Lv52
1070 积分 2024-05-06 加入
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
3天前
已完结
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
26天前
已完结
E3 ligase ligand chemistries: from building blocks to protein degraders
1个月前
已完结
Influence of gravity and light on the developmental polarity of Ceratopteris richardii fern spores
2个月前
已完结
ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion
4个月前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
4个月前
已完结
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial
4个月前
已完结
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial
4个月前
已完结
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
4个月前
已完结
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
4个月前
已完结
皖公网安备34019202002308
